We are pleased to inform you that there are new data available for IMFINZI® (durvalumab) from the CASPIAN trial’s 3-year planned exploratory analysis, including overall survival at 36 months. Approval for IMFINZI was based on the CASPIAN study, a Phase III, randomized, open-label study in 805 patients with treatment-naïve extensive-stage small cell lung cancer. Overall survival was the primary endpoint. At the time of the planned interim overall survival analysis, the median duration of follow-up was 14.2 months. [Please see the attached resource for the key study results from the CASPIAN trial.] Indication IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).